SCHEMBL20914037

SCHEMBL20914037

COc1ccccc1-c1c(C(F)(F)F)nn2c(=O)c(-c3nc4c(OC)cccc4o3)c(C)[nH]c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.39
▸ HTT P42858 3/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ F2RL3 Q96RI0 2/20 0.36
▸ ALPL P05186 1/20 0.36
▸ PLAT P00750 2/20 0.36
▸ PSEN1 P49768 1/20 0.35
▸ PSEN2 P49810 1/20 0.35
▸ APH1B Q8WW43 1/20 0.35
▸ NCSTN Q92542 1/20 0.35
▸ APH1A Q96BI3 1/20 0.35
▸ PSENEN Q9NZ42 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HTR3A P46098 2/20 0.34
▸ KCNH2 Q12809 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20913903 0.94 HTT (0.36) TSHRHTTHSD17B10F2RL3ALPL
SCHEMBL20914028 0.92 HTT (0.34) TSHRHTTHSD17B10F2RL3ALPL
SCHEMBL20819069 0.91 TNKS (0.37) TSHRHTTHSD17B10F2RL3MAPT
SCHEMBL20914243 0.90 F2RL3 (0.35) TSHRHTTHSD17B10F2RL3PLAT
SCHEMBL20914414 0.89 SMN1; SMN2 (0.37) TSHRHTTHSD17B10F2RL3PSEN1
SCHEMBL20931264 0.89 TNKS (0.39) TSHRHTTHSD17B10F2RL3PLAT
SCHEMBL20837034 0.89 TNKS (0.39) HTTF2RL3PLATPSEN1PSEN2
SCHEMBL20914062 0.88 TNKS (0.39) F2RL3MAPTMEN1KMT2ATNKS
SCHEMBL20913957 0.87 TNKS (0.34) TSHRHSD17B10F2RL3PSEN1PSEN2
SCHEMBL20914030 0.87 PSEN1 (0.35) TSHRHTTHSD17B10F2RL3PLAT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 TSHR 4008/4885HTT 165/4885HSD17B10 3047/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 TSHR 4008/4885HTT 165/4885HSD17B10 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback